Immune drug helps patients with serious kidney disorder

Rituximab is more effective and less toxic than standard therapies

2012-07-20

(Press-News.org) Highlights Patients with a particular kidney immune disorder experienced remission when taking the immune drug rituximab, even when standard therapies had failed. Rituximab was safe and well-tolerated by all patients in the study.

Each year, an estimated 70,000 people globally are diagnosed with the disorder, called idiopathic membranous nephropathy.

Washington, DC (July 19, 2012) — A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN). The findings could help people who are living with the condition, called idiopathic membranous nephropathy (IMN), avoid taking the potentially toxic medications that are currently prescribed to treat it.

Standard therapy for IMN includes nonspecific immunosuppression with steroids and other agents that do not work in all patients and can cause serious complications. Because the drug rituximab specifically targets immune cells involved in the development and progression of IMN, Piero Ruggenenti, MD, Giuseppe Remuzzi, MD, FRCP (Mario Negri Institute for Pharmacological Research and Ospedali Riuniti, in Bergamo, Italy) and their colleagues tested its safety and effectiveness in 100 patients with IMN. The looked to see how many patients experienced complete or partial remission, based on the amount of protein excreted in the urine.

Among the major findings: Over an average of 29 months, 65 out of the 100 patients taking rituximab treatment experienced remission of their disease. Twenty-seven of these patients achieved complete remission. All patients with at least four years of follow-up achieved complete or partial remission, and their kidney function improved over time. Rituximab was effective even when previous treatments with steroids and other immunosuppressive drugs had failed. Patients tolerated rituximab well and experienced no treatment-related serious side effects throughout the entire study.

"Rituximab may lead to major progress in the treatment of patients with idiopathic membranous nephropathy, and in consideration of its excellent safety profile, it might replace other toxic regimens as first line treatment of this disease," said Dr. Remuzzi.

An added benefit of rituximab is that it can be administered in one single intravenous infusion on an outpatient basis, while courses of steroids and other drugs for IMN require at least six months of continued treatment and often cause patients to become hospitalized due to complications.

###Study co-authors include Paolo Cravedi, MD, PhD, Antonietta Chianca, PhD, Annalisa Perna, StatSciD, Barbara Ruggiero, MD, Flavio Gaspari, PhD, Alessandro Rambaldi, MD, and Maddalena Marasà, MD.

Disclosures: The authors reported no financial disclosures.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

ELSE PRESS RELEASES FROM THIS DATE:

Study questions safety and effectiveness of common kidney disease drugs

2012-07-20

Highlights Phosphate binders, drugs commonly prescribed to patients with chronic kidney disease, may not be as effective as previously thought. Phosphate binders may have negative effects on cardiovascular health. Additional studies are needed on the safety and effectiveness of these drugs. Washington, DC (July 19, 2012) — Drugs commonly prescribed to patients with chronic kidney disease (CKD) may not be as strongly effective as once thought, and may cause unexpected harm to blood vessels, according to a study appearing in an upcoming issue of the Journal of ...

New technique reveals cross-talk between 2 essential cellular processes

2012-07-20

LA JOLLA, CA – Scientists at The Scripps Research Institute have simultaneously mapped two of the most important types of protein-modification in cells, revealing their extensive cooperation during an essential cellular process. Phosphorylation, the attachment of a phosphate group to a protein, and proteolysis, the cleavage of a protein, had almost always been studied independently. The new research combines techniques for mapping these events across all proteins in a cell population to show how they work together to execute the cellular "auto-destruct program" known ...

Debate ends: Everyone was right

2012-07-20

KANSAS CITY, MO—Scientists at the Stowers Institute of Medical Research have developed an innovative method to count the number of fluorescent molecules in a cluster and then applied the novel approach to settle a debate rampant among cell biologists—namely, how DNA twists into a unique chromosomal structure called the centromere. Knowing this helps explain how cells navigate the hazards of division and avoid the disastrous consequences of ending up with the wrong number of chromosomes. Centromeres, which sit at the cross point of the "X" used to represent duplicated ...

The Yin and Yang of stem cell quiescence and proliferation

2012-07-20

KANSAS CITY, MO—Not all adult stem cells are created equal. Some are busy regenerating worn out or damaged tissues, while their quieter brethren serve as a strategic back-up crew that only steps in when demand shoots up. Now, researchers at the Stowers Institute for Medical Research have identified an important molecular cue that keeps quiescent mouse hematopoietic (or blood-forming) stem cells from proliferating when their services are not needed. Publishing in the July 20, 2012 issue of Cell, the team led by Stowers Investigator Linheng Li, Ph.D., report that Flamingo ...

Lack of insurance linked to advanced stage cervical cancer

2012-07-20

ATLANTA –July 19, 2012—A large national sample of women diagnosed with cervical cancer between 2000 and 2007 finds lack of insurance was second only to age as the strongest predictor of late stage at diagnosis, a gap the authors say is likely attributable to lack of screening. The American Cancer Society estimates that 12,170 women will be diagnosed with cervical cancer and 4,220 women will die from the disease in 2012. Although incidence and mortality from cervical cancer have declined dramatically since the introduction of the Pap test, one in three cervical cancer ...

Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer

2012-07-20

PHILADELPHIA — Inhibitors of indoleamine 2,3-dioxygenase (IDO) are being assessed in clinical trials as a potential treatment for recurrent or refractory solid tumors. Clear genetic rationale for these trials, together with evidence that primary and metastatic lung tumors might be particularly susceptible to the drugs, is now reported in a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research. "Our data provide preclinical genetic validation for the ongoing clinical trials testing IDO inhibitors in cancer patients," ...

Team discovers how western corn rootworm resists crop rotation

2012-07-20

CHAMPAIGN, Ill. — A new study answers a question that has baffled researchers for more than 15 years: How does the western corn rootworm – an insect that thrives on corn but dies on soybeans – persist in fields that alternate between corn and soybeans? The answer, researchers say, has to do with enzyme production in the rootworm gut. Their findings are described in a paper in Ecology and Evolution. Crop rotation declined in the middle of the 20th century as the use of insecticides and fertilizers expanded in the U.S. Then in the 1950s and '60s, when some insecticides ...

NYU Langone Medical Center's tip sheet to the Alzheimer's Association International Conference

2012-07-20

NEW YORK, JULY 15, 2012 – Experts from the Comprehensive Center on Brain Aging at NYU Langone Medical Center will present new research at The 2012 Alzheimer's Association International Conference on Alzheimer's Disease to be held in Vancouver, British Columbia, Canada, July 14 – July 19. From basic discovery to clinical applications, NYU Langone Medical Center has been at the forefront of the diagnosis and treatment of Alzheimer's disease since the 1970s. The Comprehensive Center on Brain Aging, founded upon the strengths of the Silberstein Alzheimer's Institute, is ...

Locating muscle proteins

2012-07-20

Muscle contraction and many other movement processes are controlled by the interplay between myosin and actin filaments. Two further proteins, tropomyosin and troponin, regulate how myosin binds to actin. While theoretical models have in fact described exactly how these muscle proteins interact, this interaction has never previously been observed in detail. Stefan Raunser and Elmar Behrmann from the Max Planck Institute of Molecular Physiology in Dortmund have now managed to image the actin-myosin-tropomyosin complex with an unprecedented accuracy of 0.8 nanometres, which ...

Stanford researchers first to determine entire genetic sequence of individual human sperm

2012-07-20

STANFORD, Calif. — The entire genomes of 91 human sperm from one man have been sequenced by Stanford University researchers. The results provide a fascinating glimpse into naturally occurring genetic variation in one individual, and are the first to report the whole-genome sequence of a human gamete — the only cells that become a child and through which parents pass on physical traits. "This represents the culmination of nearly a decade of work in my lab," said Stephen Quake, PhD, the Lee Otterson Professor in the School of Engineering and professor of bioengineering ...

Korea University College of Medicine and Yale Univeristy co-host forum on Advancing Healthcare through Data and AI Innovations

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Dronedarone inhibits the proliferation of esophageal squamous cell carcinoma through the CDK4/CDK6-RB1 axis in vitro and in vivo

[Press-News.org] Immune drug helps patients with serious kidney disorder
Rituximab is more effective and less toxic than standard therapies

Immune drug helps patients with serious kidney disorder

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: